About Blade Therapeutics
Blade Therapeutics is a Healthcare company based in San Francisco (United States) founded in 2015. Antifibrotic strategies are developed for congenital and acquired fibrotic diseases. Blade Therapeutics has raised $93 million across 3 funding rounds from investors including Novartis, Bristol-Myers Squibb and OneVentures. The company has 30 employees. Its focus areas include Life Sciences, Immunology, Drugs and Fibrosis. Its legal entity is BLADE THERAPEUTICS, INC. Its competitors include Reneo Pharmaceuticals, Sionna and Arcturus Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Blade Therapeutics is a discovery stage drug development company. The companys mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. The company exploits novel target biology to halt the progression of fibrosis. The technology is licensed from Johns Hopkins University School of Medicine and is based on the research from the laboratory of Harry Dietz, the Victor A. McKusick Professor of Genetics in the Institute of Genetic Medicine at Johns Hopkins University School of Medicine.
- Headquarters San Francisco, United States
- Employees 30
- SectorsHealthcare
- Website blademed.com
- Social LinkedIn
- Legal Name Blade Therapeutics, Inc.
- Total Equity Funding$93M (USD)
in 3 rounds
- Latest Funding Round$38M (USD), Series C
Oct 2019
- InvestorsNovartis
& 6 more
- Employee Count30
Funding Insights of Blade Therapeutics
Blade Therapeutics has successfully raised a total of $93M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $38 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $93M
- Total Rounds 3
- Last Round Series C — $38M
- First Round $45M
(Jun 2016)
- Investors Count 7
All 3 funding rounds of Blade Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2019 | $38M | Series C | – | – | – |
| Nov 2018 | $10M | Series C | – | One Ventures | – |
| Jun 2016 | $45M | Series B | – | Deerfield |
7 investors in total: 7 institutional.
Investors in Blade Therapeutics
Blade Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Bristol-Myers Squibb and OneVentures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm offering growth equity and credit for technology and healthcare companies. | one-ventures.com.au | |||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
Venture capital is focused on healthcare by Pfizer's investment arm. | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | ||
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland | |
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States | |
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com |
Investor details for Blade Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Blade Therapeutics
3 dated milestones of Blade Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Blade Therapeutics is founded.
- Funding First funding round of $45.0M.
- Funding Latest funding round, Series C, of $38.0M.
Competitors of Blade Therapeutics
Blade Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Reneo Pharmaceuticals, Sionna and Arcturus Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| reneopharma.com | 2015 | San Diego, United States | $145M | 48 | Small molecule therapies for orphan diseases are being developed. | |
| sionnatx.com | 2019 | Natick, United States | $293M | Small molecule therapeutics for cystic fibrosis are developed. | ||
| arcturusrx.com | 2013 | San Diego, United States | $1.3M | 337 | RNAi technologies are developed for treating rare orphan diseases. |
Detailed competitors of Blade Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Blade Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Blade Therapeutics
Complete news archive for Blade Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Blade Therapeutics
Blade Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Blade Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Blade Therapeutics is a funded company, having raised a total of $93M across 3 funding rounds to date. The company's 1st funding round was a Series B of $45M, raised on Jun 2016.
Blade Therapeutics has 30 employees.
Blade Therapeutics is a discovery stage drug development company. The companys mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. The company exploits novel target biology to halt the progression of fibrosis. The technology is licensed from Johns Hopkins University School of Medicine and is based on the research from the laboratory of Harry Dietz, the Victor A. McKusick Professor of Genetics in the Institute of Genetic Medicine at Johns Hopkins University School of Medicine.
Blade Therapeutics's top competitors include Arcturus Therapeutics, Reneo Pharmaceuticals and Sionna.
Blade Therapeutics has 7 investors. Key investors include Novartis, Bristol-Myers Squibb, OneVentures, Deerfield, and Turmeric Acquisition Corp.
Blade Therapeutics operates through Blade Therapeutics, Inc..